Article
The treatment was well tolerated. Most adverse events were mild and consisted primarily of irritation or erythema at the site of application.
Reflecting on the Growth of NPs and PAs in Dermatology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Bridging Therapeutic Innovation and Dermatology
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin
Study Reveals Immune Checkpoint Inhibitor Treatment and Monitoring Practices Post-Remission